Company Description
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases.
Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract.
The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA.
The company has a strategic research collaboration with KU Leuven and University Hospitals Leuven to investigate the effects of NX-13 on epithelial cells with the inflammatory bowel disease.
The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
| Country | United States |
| Founded | 2017 |
| IPO Date | Feb 4, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Ms. Jennifer Creel |
Contact Details
Address: 1800 Kraft Drive, Suite 216 Blacksburg, Virginia 24060 United States | |
| Phone | 540-818-2844 |
| Website | landosbiopharma.com |
Stock Details
| Ticker Symbol | LABP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001785345 |
| CUSIP Number | 515069102 |
| ISIN Number | US5150692011 |
| Employer ID | 81-5085535 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gregory Oakes | President, Chief Executive Officer and Director |
| Dr. Fabio Cataldi M.D. | Executive Vice President and Chief Medical Officer |
| Jennifer Creel | Interim Chief Financial Officer |
| Rebecca Mosig Ph.D. | Vice President of Corporate Development |
| Dr. Josep Bassaganya-Riera DVM, Ph.D. | Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 10-K/A | [Amend] Annual report |
| Apr 15, 2024 | PREM14A | Filing |
| Apr 10, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 10, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 21, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 21, 2024 | 10-K | Annual Report |